Keros Therapeutics, Inc. KROS
We take great care to ensure that the data presented and summarized in this overview for Keros Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding KROS
View all-
Black Rock Inc. New York, NY2.17MShares$106 Million0.0% of portfolio
-
Alkeon Capital Management LLC New York, NY1.6MShares$78.1 Million0.18% of portfolio
-
State Street Corp Boston, MA1.56MShares$76.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.55MShares$75.5 Million0.0% of portfolio
-
Darwin Global Management, Ltd. St. Helier, Y91.44MShares$70.2 Million16.21% of portfolio
-
Orbimed Advisors LLC San Diego, CA1.27MShares$62 Million1.89% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD1.22MShares$59.5 Million0.01% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct972KShares$47.5 Million0.16% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA879KShares$43 Million6.13% of portfolio
-
Woodline Partners LP San Francisco, CA762KShares$37.2 Million0.48% of portfolio
Latest Institutional Activity in KROS
Top Purchases
Top Sells
About KROS
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, and is currently in Phase 1 clinical trial; and KER-012, which is in Phase 1 clinical trial to treat disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
Insider Transactions at KROS
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 04
2023
|
Keith Regnante CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
40,000
-100.0%
|
$1,800,000
$45.29 P/Share
|
|
Nov 04
2023
|
Keith Regnante CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+50.0%
|
$640,000
$16.0 P/Share
|
|
Jun 09
2023
|
Keith Regnante CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
20,000
-71.87%
|
$920,000
$46.25 P/Share
|
|
Jun 09
2023
|
Keith Regnante CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+50.0%
|
$320,000
$16.0 P/Share
|
|
Jun 08
2023
|
Keith Regnante CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
20,000
-93.25%
|
$960,000
$48.16 P/Share
|
|
Jun 08
2023
|
Keith Regnante CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+50.0%
|
$320,000
$16.0 P/Share
|
|
Apr 08
2023
|
Jasbir Seehra CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+1.56%
|
$0
$0.48 P/Share
|
|
Nov 29
2022
|
Tomer Kariv |
SELL
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
7,176
-0.15%
|
-
|
|
Nov 29
2022
|
Ran Nussbaum |
SELL
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
7,176
-0.15%
|
-
|
|
Nov 29
2022
|
Pontifax Management 4 G.P. (2015) Ltd. > 10% Shareholder |
SELL
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
7,176
-0.15%
|
-
|
|
Jul 15
2022
|
Jennifer Lachey Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
46,034
-32.62%
|
$1,381,020
$30.0 P/Share
|
|
Jul 15
2022
|
Jennifer Lachey Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
46,034
+24.6%
|
$0
$0.3 P/Share
|
|
Jul 13
2022
|
Jennifer Lachey Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,916
-1.97%
|
$57,480
$30.0 P/Share
|
|
Jul 13
2022
|
Jennifer Lachey Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,916
+2.01%
|
$0
$0.3 P/Share
|
|
Jun 14
2022
|
Jennifer Lachey Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,400
+9.0%
|
$0
$0.3 P/Share
|
|
Jun 09
2022
|
Jasbir Seehra CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+1.97%
|
$0
$0.3 P/Share
|
|
May 11
2022
|
Jennifer Lachey Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
5,300
-1.18%
|
$227,900
$43.35 P/Share
|
|
May 11
2022
|
Jennifer Lachey Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,300
+5.5%
|
$0
$0.3 P/Share
|
|
Apr 11
2022
|
Jennifer Lachey Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
5,300
-1.49%
|
$328,600
$62.84 P/Share
|
|
Apr 11
2022
|
Jennifer Lachey Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,300
+5.5%
|
$0
$0.3 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 40K shares |
|---|
| Open market or private sale | 40K shares |
|---|